This article explores androgen receptor (AR) genomic alterations and their role in treatment resistance in metastatic prostate cancer. The study highlights how mutations, amplifications, and splice variants of the AR contribute to resistance against androgen deprivation therapy (ADT) and other targeted treatments. The article discusses the mechanisms by which AR
